Azithromycin decreases crevicular fluid volume and mediator content.
Azithromycin enhances the response to root planing and produces anti-inflammatory effects in treating chronic lung disease. This led us to hypothesize that azithromycin inhibits inflammatory mediator production in gingiva, leading to decreased gingival crevicular fluid (GCF) volume. To test this hypothesis, ten periodontally healthy volunteers received azithromycin every 24 hours for 48 hours. GCF samples were collected from 12 maxillary interproximal sites prior to azithromycin (baseline) and 2, 4, 7, and 14 days later. Samples were assayed for IL-1beta, IL-8, TNF-alpha, VEGF, IL-6, and IL-10. With azithromycin treatment, GCF volume decreased significantly on days 2 through 7 (P < 0.05), but increased toward baseline levels on day 14. This was accompanied by a transient decrease in the content of IL-1beta, IL-8, TNF-alpha, and VEGF (P < 0.05). IL-6 and IL-10 were not detected. Since plaque was absent throughout the study, the findings suggest that azithromycin produces anti-inflammatory effects in gingiva.
Ho
W
W
Division of Periodontology, College of Dentistry, 305 West 12th Avenue.
Eubank
T
T
Leblebicioglu
B
B
Marsh
C
C
Walters
J
J
D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology*; D016207:Cytokines / Q000032:analysis / Q000096:biosynthesis*; D005883:Gingival Crevicular Fluid / Q000737:chemistry* / Q000187:drug effects; D006801:Humans; D007150:Immunohistochemistry; D018836:Inflammation Mediators / Q000032:analysis / Q000378:metabolism*; D016753:Interleukin-10 / Q000032:analysis; D053583:Interleukin-1beta; D015850:Interleukin-6 / Q000032:analysis; D016209:Interleukin-8 / Q000032:analysis; D011446:Prospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis
D000900:Anti-Bacterial Agents; D016207:Cytokines; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D016753:Interleukin-10; D017963:Azithromycin
Biochem Biophys Res Commun. 2000 Jan 7;267(1):124-8
10623585
Antimicrob Agents Chemother. 1999 Nov;43(11):2801-5
10543769
Antimicrob Agents Chemother. 1992 Jun;36(6):1241-3
1329617
J Clin Periodontol. 2002 Jan;29(1):48-53
11846849
Acta Odontol Scand. 1963 Dec;21:533-51
14121956
J Clin Periodontol. 2002 Jan;29(1):54-61
11846850
Int J Antimicrob Agents. 2001;18 Suppl 1:S11-5
11574189
Am J Transplant. 2007 Jan;7(1):76-82
17061983
J Periodontol. 2000 Sep;71(9):1448-52
11022774
Acta Odontol Scand. 1964 Feb;22:121-35
14158464
Int J Antimicrob Agents. 2008 Jan;31(1):12-20
17935949
J Periodontol. 2007 May;78(5):918-23
17470027
J Dent Res. 2005 Jan;84(1):9-20
15615869
J Periodontol. 1992 Sep;63(9):743-7
1474474
J Periodontol. 2007 Sep;78(9):1783-7
17760549
Periodontol 2000. 2003;31:32-42
12656994
Infect Immun. 1995 Oct;63(10):3878-85
7558295
Periodontol 2000. 1996 Feb;10:45-78
9567937
J Periodontol. 2003 Feb;74(2):181-7
12666706
J Periodontal Res. 1998 Nov;33(8):491-9
9879523
Crit Rev Oral Biol Med. 1998;9(3):248-66
9715365
Periodontol 2000. 1997 Jun;14:33-53
9567965
J Periodontol. 1987 Aug;58(8):529-39
3305856
J Periodontol. 2008 Sep;79(9):1712-8
18771373
J Clin Periodontol. 2002 Dec;29(12):1082-5
12492908
J Clin Periodontol. 2008 Aug;35(8):696-704
18631245
Arch Oral Biol. 1973 Jul;18(7):899-923
4516188
J Antimicrob Chemother. 2002 May;49(5):745-55
12003967
Oral Microbiol Immunol. 1993 Oct;8(5):325-6
8265209
J Periodontol. 2005 Mar;76(3):426-36
15857078
Am J Physiol Lung Cell Mol Physiol. 2006 Jan;290(1):L75-85
16085674
Am J Med. 2004 Nov 8;117 Suppl 9A:5S-11S
15586558
J Dent Res. 2008 Aug;87(8):777-81
18650552
J Periodontol. 2007 Mar;78(3):453-8
17335368
Periodontol 2000. 1999 Jun;20:82-121
10522224